WELLESLEY HILLS, Massachusetts, June 8 /PRNewswire/ --
Joseph F. Finn, Jr., C.P.A. (Finn) announced today that he has received a statement from Ludwig Institute of Cancer Research Ltd., Brussels Branch. The statement is quoted in its entirety below.
Prospect Therapeutics' lead product candidate, GCS-100, is a carbohydrate molecule which inhibits the activity of Galectin-3, a protein found in high concentration in a broad range of human cancers. Prospect reported that GCS-100 could induce apoptosis of cancer cells and that clinical trial results indicated that reduction in leukemic cell number could be obtained without severe side effects.